on Moderna, Inc. (NASDAQ:MRNA)
Moderna delivers first Canadian-made mRNA vaccines
Moderna has announced the shipment of the first mRNA vaccines manufactured in Canada to various provinces and territories. This milestone marks a significant step forward in the country's vaccine production autonomy, strengthening its health security. The vaccines are produced in Laval, Quebec, with packaging carried out in Ontario by Novocol Pharma.
The vaccine targeting the SARS-CoV-2 LP.8.1 variant received Health Canada approval on August 21, 2025, as well as international approvals. Moderna is pursuing global regulatory submissions for the upcoming respiratory virus season.
Each province will determine its own vaccination schedule and eligibility criteria, ensuring free access to eligible individuals. Discussions are underway with the private sector to ensure broader access.
R. E.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Moderna, Inc. news